Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7711 to 7725 of 8905 results

  1. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    We have moved Diagnostics guidance 19 to become HealthTech guidance 388. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    We have moved Diagnostics guidance 18 to become HealthTech guidance 386. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

    This guideline has been updated and replaced by NICE guideline NG131.

    Withdrawn guidance

  5. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

    Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

    Withdrawn guidance

  6. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)

    We have moved Diagnostics guidance 20 to become HealthTech guidance 400. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21)

    This guidance has been updated and replaced by NICE technology appraisal guidance 943.

    Withdrawn guidance

  8. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

    We have moved Diagnostics guidance 22 to become HealthTech guidance 401. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) (DG23)

    This guidance has been updated and replaced by NICE healthtech guidance 630.

    Withdrawn guidance

  10. ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)

    We have moved Diagnostics guidance 24 to become HealthTech guidance 413. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)

    We have moved Diagnostics guidance 25 to become HealthTech guidance 420. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) (DG26)

    July 2022: The guidance has been withdrawn because PCR tests now form part of standard care. Since the diagnostics guidance was published, expert advice suggests that clinical practice has moved on; PCR testing using a centralised approach is widely available in the NHS and adoption is growing. The UK standards for Microbiology Investigation also provide additional support for the PCR-based diagnostic tests.

    Withdrawn guidance

  13. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

    We have moved Diagnostics guidance 27 to become HealthTech guidance 430. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    We have moved Diagnostics guidance 29 to become HealthTech guidance 441. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

    We have moved Diagnostics guidance 3 to become HealthTech guidance 281. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance